

PRODUCT INFORMATION



Irinotecan (hydrochloride hydrate)

Item No. 14180

CAS Registry No.: 136572-09-3
Formal Name: [1,4'-bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride, trihydrate

MF: C₃₃H₃₈N₄O₆ • HCl [3H₂O]

FW: 677.2


Purity: ≥98%

UV/Vis.: λ_{max}: 221, 356, 360 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Irinotecan (hydrochloride hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the irinotecan (hydrochloride hydrate) in the solvent of choice, which should be purged with an inert gas. Irinotecan (hydrochloride hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of irinotecan (hydrochloride hydrate) in these solvents is approximately 20 mg/ml.

Irinotecan (hydrochloride hydrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, irinotecan (hydrochloride hydrate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Irinotecan (hydrochloride hydrate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Irinotecan, a derivative of the alkaloid camptothecin (Item No. 11694), functions as a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin, a potent inhibitor of DNA topoisomerase I.^{1,2} Its action is terminated by glucuronidation by UDP glucuronosyl transferase 1A1.^{3,4} Irinotecan demonstrates a broad spectrum of antitumor activity against metastatic colorectal cancer, small cell lung cancer, and several other solid tumors and has proven useful in radiation treatment of tumors by sensitizing tissue to radiation damage.^{1,2}

References

1. Rothenberg, M.L. Topoisomerase I inhibitors: Review and update. *Ann. Oncol.* **8(9)**, 837-855 (1997).
2. Dancey, J. and Eisenhauer, E.A. Current perspectives on camptothecins in cancer treatment. *Br. J. Cancer* **74(3)**, 327-338 (1996).
3. Mathijssen, R.H.J., van Alphen, R.J., Verweij, J., *et al.* Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). *Clin. Cancer Res.* **7(8)**, 2182-2194 (2001).
4. Ma, M.K. and McLeod, H.L. Lessons learned from the irinotecan metabolic pathway. *Curr. Med. Chem.* **10(1)**, 41-49 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM